IPO registrations (S-1, F-1) · Registrants
enVVeno Medical Corp
- SEC CIK
- 1661053 · filings on EDGAR ↗
- Name on the registration
- Hancock Jaffe Laboratories, Inc.
- Former names
- Hancock Jaffe Laboratories, Inc. (2015–2021)
- Registration
- Form S-1, first filed 2017-09-07, last 2021-02-05; 8 initial registrations, 14 amendments
- Outcome
- Final prospectus filed 2018-06-01; declared effective 2018-05-30
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- DE
- Business address
- 70 DOPPLER, Irvine, CA 92618
- EIN
- 33-0936180
- Ticker
- NVNO (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- enVVeno Medical Corp on the corporate pages
Offering terms
- Final price
- $5.00 per share (424B4 filed 2018-06-01, an initial public offering)
- Shares sold
- 1,500,000
- Gross proceeds
- $7,500,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol HJLI
- Lead underwriters
- Network 1 Financial
- Syndicate
- of Contents
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: ENVVENO MEDICAL CORPORATION EXACT (EIN (EXACT))
- Form D issuer: Hancock Jaffe Laboratories, Inc. EXACT (CIK (EXACT))
- SEC filer: enVVeno Medical Corp EXACT (CIK (EXACT))
Filings 41
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-09-07 | S-1 | S-1 (registration) | Hancock Jaffe Laboratories, Inc. | 0001493152-17-010302 ↗ |
| 2017-11-06 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-17-012423 ↗ |
| 2017-12-05 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-17-014183 ↗ |
| 2017-12-14 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-17-014595 ↗ |
| 2018-01-26 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-001116 ↗ |
| 2018-04-16 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-005159 ↗ |
| 2018-05-14 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-006831 ↗ |
| 2018-05-22 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-007670 ↗ |
| 2018-05-30 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-007970 ↗ |
| 2018-05-30 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-18-001373 ↗ |
| 2018-05-31 | S-1MEF | S-1MEF (added securities) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-008031 ↗ |
| 2018-06-01 | 424B4 | 424B4 (final prospectus) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-008137 ↗ |
| 2018-06-01 | 424B4 | 424B4 (final prospectus) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-008138 ↗ |
| 2018-06-12 | S-1 | S-1 (registration) | Hancock Jaffe Laboratories, Inc. | 0001493152-18-008510 ↗ |
| 2018-06-20 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-18-001563 ↗ |
| 2019-03-29 | S-1 | S-1 (registration) | Hancock Jaffe Laboratories, Inc. | 0001493152-19-004206 ↗ |
| 2019-04-29 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-19-000899 ↗ |
| 2019-05-06 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-19-001013 ↗ |
| 2019-06-07 | S-1 | S-1 (registration) | Hancock Jaffe Laboratories, Inc. | 0001493152-19-008890 ↗ |
| 2019-06-11 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-19-001330 ↗ |
| 2019-06-13 | 424B4 | 424B4 (final prospectus) | Hancock Jaffe Laboratories, Inc. | 0001493152-19-009147 ↗ |
| 2020-04-16 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-20-000777 ↗ |
| 2020-06-15 | S-1 | S-1 (registration) | Hancock Jaffe Laboratories, Inc. | 0001493152-20-011201 ↗ |
| 2020-06-23 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-20-001515 ↗ |
| 2020-07-02 | S-1 | S-1 (registration) | Hancock Jaffe Laboratories, Inc. | 0001493152-20-012514 ↗ |
| 2020-07-13 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-20-013174 ↗ |
| 2020-07-16 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-20-013425 ↗ |
| 2020-07-16 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-20-001833 ↗ |
| 2020-07-20 | 424B4 | 424B4 (final prospectus) | Hancock Jaffe Laboratories, Inc. | 0001493152-20-013579 ↗ |
| 2020-10-22 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-20-002945 ↗ |
| 2020-11-06 | S-1 | S-1 (registration) | Hancock Jaffe Laboratories, Inc. | 0001493152-20-020711 ↗ |
| 2020-11-24 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-20-022408 ↗ |
| 2020-11-30 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-20-003333 ↗ |
| 2020-12-21 | S-1 | S-1 (registration) | Hancock Jaffe Laboratories, Inc. | 0001493152-20-023963 ↗ |
| 2021-01-28 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-21-002041 ↗ |
| 2021-02-03 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-21-002430 ↗ |
| 2021-02-05 | S-1/A | S-1/A (amendment) | Hancock Jaffe Laboratories, Inc. | 0001493152-21-002800 ↗ |
| 2021-02-08 | S-1MEF | S-1MEF (added securities) | Hancock Jaffe Laboratories, Inc. | 0001493152-21-003009 ↗ |
| 2021-02-08 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-21-000488 ↗ |
| 2021-02-10 | 424B4 | 424B4 (final prospectus) | Hancock Jaffe Laboratories, Inc. | 0001493152-21-003125 ↗ |
| 2021-05-06 | EFFECT | EFFECT (declared effective) | Hancock Jaffe Laboratories, Inc. | 9999999995-21-001812 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-05-30 | S-1/A | registration statement | $5.00 | - | - | 0 | primary document; price line | document ↗ | ||
| 2018-06-01 | 424B4 | final prospectus | $5.00 | 1,500,000 | $7,500,000 | Nasdaq HJLI | 2 | primary document; price sentence, shares headline, proceeds table, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ABBOTT WILLIAM R | Officer | See Remarks. | 1 | 2018 | |
| Anderson Robert A. | Director | 1 | 2018 | ||
| BERMAN ROBERT ANDREW | Director,Officer; Officer | CEO; Chief Executive Officer | 16 | 2018–2025 | |
| Biodyne Holding, S.A. | Other; TenPercentOwner | 7 | 2018–2020 | ||
| Broennimann Benedict | Officer | Chief Medical Officer, OUS | 2 | 2018 | |
| Browston Trading Ltd | TenPercentOwner | 2 | 2018–2019 | ||
| Cantor Steven A. | TenPercentOwner | 1 | 2018 | ||
| Doyle Robert W. | Director | 1 | 2018 | ||
| GIRGENTI STEVEN | Director | 1 | 2018 | ||
| Glickman Marc H. | Officer | CMO and Senior Vice President; See Remarks; SVP & Chief Medical Officer; SVP & CMO | 9 | 2018–2025 | |
| Montoya Susan | Officer | See Remarks | 1 | 2018 | |
| Zhivilo Yury | Director,TenPercentOwner | 2 | 2018–2019 | ||
| Rankin Robert A | Officer | Chief Financial Officer | 1 | 2018 | |
| Robins Marcus W. | Director | 2 | 2018 | ||
| Shrivastava Sanjay | Director | 13 | 2018–2025 | ||
| Duhay Francis | Director | 17 | 2018–2026 | ||
| Gray Robert | Director | 13 | 2019–2025 | ||
| Jenusaitis Matthew | Director | 12 | 2020–2025 | ||
| Glynn Craig | Officer | Chief Financial Officer | 4 | 2021–2023 | |
| Alavi Hamed | Officer | Chief Technology Officer | 5 | 2023–2025 | |
| Bright Jennifer | Officer | Chief Financial Officer | 2 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-08-04 | Hancock Jaffe Laboratories, Inc. | Biotechnology | $1,556,000 | $1,556,000 | 4 | 1 |
| 2020-03-10 | Hancock Jaffe Laboratories, Inc. | Biotechnology | $890,000 | $650,000 | 9 | 1 |
| 2019-04-16 | Hancock Jaffe Laboratories, Inc. | Biotechnology | $2,704,000 | $2,704,000 | 105 | 2 |
| 2017-06-26 | Hancock Jaffe Laboratories, Inc. | Biotechnology | $2,000,000 | $1,000,000 | 4 | 1 |
| 2017-03-22 | Hancock Jaffe Laboratories, Inc. | Biotechnology | $7,500,000 | $194,000 | 4 | 1 |
| 2015-12-15 | Hancock Jaffe Laboratories, Inc. | Biotechnology | $6,500,000 | $680,000 | 10 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | ENVVENO MEDICAL CORPORATION | CA | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | Hancock Jaffe Laboratories, Inc. | CA | Form D private offerings | CIK (EXACT) |
| Patent assignee | enVVeno Medical Corporation | CA | Patents (USPTO) | name and state |
| SEC filer | enVVeno Medical Corp | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | ENVVENO MEDICAL CORPORATION | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | ENVVENO MEDICAL CORPORATION | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Surgical & Medical Instruments & Apparatus, CA first:
- FUSION MEDICAL TECHNOLOGIES INC CA
- ENDOLOGIX INC /DE/ CA
- CEMAX ICON INC CA
- TRYLON CORP CA
- R2 TECHNOLOGY INC CA
- CERUS CORP CA
- SOMNUS MEDICAL TECHNOLOGIES INC CA
- MICRUS ENDOVASCULAR CORP CA
- AEROGEN INC CA
- IOMED LLC CA
In other datasets, the same topic (Technology) in CA:
- Lobbying client: 8X8, INC. (Federal lobbying (LDA))
Interests: Surgical & Medical Instruments & Apparatus · Technology